Cargando…

Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice

BACKGROUND: The randomised double-blinded placebo-controlled EXIST-1–3 studies have showed everolimus effective with adverse effects reported as acceptable in treatment of symptoms in patients with tuberous sclerosis complex (TSC), although evidence of outcomes in clinical practice remains limited....

Descripción completa

Detalles Bibliográficos
Autores principales:	Cockerell, Ine, Christensen, Jakob, Hoei-Hansen, Christina E., Holst, Lotte, Grenaa Frederiksen, Mikkel, Issa-Epe, Aart Imran, Nedregaard, Bård, Solhoff, Ragnar, Heimdal, Ketil, Johannessen Landmark, Cecilie, Lund, Caroline, Nærland, Terje
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693167/ https://www.ncbi.nlm.nih.gov/pubmed/38042867 http://dx.doi.org/10.1186/s13023-023-02982-1

Ejemplares similares

Modifications of Antiepileptic Drugs for Improved Tolerability and Efficacy
por: Landmark, Cecilie Johannessen, et al.
Publicado: (2008)

Antiepileptic Drug Interactions - Principles and Clinical Implications
por: Johannessen, Svein I, et al.
Publicado: (2010)

Renal manifestations of tuberous sclerosis complex: patients’ and parents’ knowledge and routines for renal follow-up – a questionnaire study
por: Cockerell, I., et al.
Publicado: (2018)

Everolimus for treatment of tuberous sclerosis complex‐associated neuropsychiatric disorders
por: Krueger, Darcy A., et al.
Publicado: (2017)

Prevalence of Different Combinations of Antiepileptic Drugs and CNS Drugs in Elderly Home Care Service and Nursing Home Patients in Norway
por: Halvorsen, Kjell H., et al.
Publicado: (2016)

Fibrous Plaque of the Eyelid in a Patient with Tuberous Sclerosis Responding to Everolimus
por: Park, Sung-Min, et al.
Publicado: (2018)

Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures
por: Franz, David N., et al.
Publicado: (2018)

Everolimus induced organizing pneumonia in a patient with tuberous sclerosis complex
por: Lanfranco, Julio, et al.
Publicado: (2021)

Effect of everolimus on multifocal micronodular pneumocyte hyperplasia in tuberous sclerosis complex
por: Daccord, Cécile, et al.
Publicado: (2020)

Everolimus and intensive behavioral therapy in an adolescent with tuberous sclerosis complex and severe behavior()()()
por: Gipson, Tanjala T., et al.
Publicado: (2013)

Erratum: Fibrous Plaque of the Eyelid in a Patient with Tuberous Sclerosis Responding to Everolimus
por: Park, Sung-Min, et al.
Publicado: (2018)

Effect and Complications of Everolimus Use for Giant Cardiac Rhabdomyomas with Neonatal Tuberous Sclerosis
por: Shibata, Yuka, et al.
Publicado: (2019)

Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis
por: Beiske, Georg Anton Giæver, et al.
Publicado: (2015)

Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives
por: Overwater, Iris E, et al.
Publicado: (2019)

The Effect of Everolimus on Subependymal Giant Cell Astrocytoma (SEGA) in Children with Tuberous Sclerosis Complex
por: BAKHTIARY, Hassan, et al.
Publicado: (2021)

Sequential everolimus for angiomyolipoma associated with tuberous sclerosis complex: a prospective cohort study
por: Gu, Liangyou, et al.
Publicado: (2021)

Resolution of multifocal micronodular pneumocyte hyperplasia with everolimus in a patient with tuberous sclerosis complex
por: Shoji, Tetsuaki, et al.
Publicado: (2021)

Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex
por: Luo, Cong, et al.
Publicado: (2021)

Stick or twist: Everolimus for seizures in tuberous sclerosis complex during the COVID-19 pandemic
por: Moloney, Patrick B., et al.
Publicado: (2021)

Individualized everolimus treatment for tuberous sclerosis-related angiomyolipoma promotes treatment adherence and response
por: Chung, Noelle K X, et al.
Publicado: (2022)

Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines
por: Reimers, Arne, et al.
Publicado: (2018)

A retrospective review of changes and challenges in the use of antiseizure medicines in Dravet syndrome in Norway
por: Heger, Katrine, et al.
Publicado: (2020)

Development and validation of a new non-disease-specific survey tool to assess self-reported adherence to medication
por: Larsen, Rønnaug Eline, et al.
Publicado: (2022)

TuberOus SClerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex
por: Kingswood, J. Chris, et al.
Publicado: (2021)

Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy
por: Capal, Jamie K, et al.
Publicado: (2016)

Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide
por: Davies, Mark, et al.
Publicado: (2017)

Pilot study evaluating everolimus molecular mechanisms in tuberous sclerosis complex and focal cortical dysplasia
por: Leitner, Dominique F., et al.
Publicado: (2022)

Everolimus as a therapeutic option in refractory epilepsy in children with tuberous sclerosis: a systematic review
por: Menezes, Catarina Ester Gomes, et al.
Publicado: (2023)

Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis
por: Bissler, John J., et al.
Publicado: (2018)

Mutational analysis of renal angiomyolipoma associated with tuberous sclerosis complex and the outcome of short-term everolimus therapy
por: Ni, Jianxin, et al.
Publicado: (2019)

Age-related changes in behavioural and emotional problems in Smith–Magenis syndrome measured with the Developmental Behavior Checklist
por: Nag, Heidi Elisabeth, et al.
Publicado: (2020)

Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex
por: Franz, David Neal
Publicado: (2013)

Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy
por: Wheless, James W.
Publicado: (2015)

Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation
por: Hwang, Su-Kyeong, et al.
Publicado: (2016)

The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial
por: Randell, Elizabeth, et al.
Publicado: (2016)

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study
por: Franz, David N., et al.
Publicado: (2016)

EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex
por: Fogarasi, Andras, et al.
Publicado: (2016)

Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial
por: Robles, Nicolás Roberto, et al.
Publicado: (2016)

Abnormal serum microRNA profiles in tuberous sclerosis are normalized during treatment with everolimus: possible clinical implications
por: Trelinska, Joanna, et al.
Publicado: (2016)

Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial
por: Cai, Yi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1bd0aqqepgvoqqr0hnqas0dcj5